Banting Memorial Lecture 2014* Technology and diabetes care: appropriate and personalized

Area of Science:

• Endocrinology and Metabolic Diseases
• Biomedical Engineering
• Personalized Medicine

Background:

• Continuous subcutaneous insulin infusion (CSII) evolved from a research tool to a standard therapy for Type 1 diabetes.
• Diabetes technologies like CSII and continuous glucose monitoring (CGM) are evidence-based but face utilization challenges.
• Conflicting meta-analysis results create confusion regarding the effectiveness and optimal application of diabetes technologies.

Observation:

• Traditional meta-analyses including all trials are unsuitable for clinical and economic decisions.
• Appropriate meta-analyses should focus on patient subgroups likely to benefit from specific technologies.
• Individual patient data meta-analysis enables covariate modeling to determine technology effectiveness, such as with CGM.

Findings:

• CSII is most beneficial for individuals with persistent hypoglycemia or uncontrolled HbA1c.
• CGM effectiveness is influenced by baseline HbA1c and sensor usage frequency.
• Diabetes technology exemplifies personalized medicine, requiring targeted evaluation and application.

Implications:

• Future diabetes technologies, including patch pumps, closed-loop systems, and nanomedicine, will also require personalized evaluation.
• Research into non-invasive glucose monitoring and islet cell encapsulation advances personalized diabetes care.
• Targeted application of diabetes technologies ensures optimal patient outcomes and resource allocation.